SCHEDULE: Deep Track Capital Discloses 5.3% Stake in Viridian
Schedule 13G
Deep Track Capital, LP and David Kroin have filed a Schedule 13G reporting a 5.3% beneficial ownership stake in Viridian Therapeutics, Inc.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have collectively acquired 5,417,660 shares of Viridian Therapeutics, Inc. common stock.
- This holding represents 5.3% of the company's total outstanding shares.
- The filing is a Schedule 13G, indicating the investment is passive in nature and not intended to influence or change control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure of an institutional position change.
Positives
- Institutional investor confidence demonstrated by the accumulation of a significant 5.3% equity position.
Negatives
- None identified in this regulatory disclosure.
Risks
- The investment is subject to market volatility inherent in the biotechnology sector.
- The filing confirms the stake is passive, limiting the investor's ability to influence corporate strategy.
Future Outlook
The reporting persons state that the securities were acquired for investment purposes and not to influence the control of the issuer.
Industry Context
StockSavvy.ai notes that institutional accumulation of biotech stocks often signals confidence in the company's clinical pipeline or potential for future M&A activity, though this specific filing is a standard passive disclosure.
Comparison to Industry Standards
- The filing follows standard regulatory requirements for institutional investors crossing the 5% ownership threshold in a public company.
Stakeholder Impact
- Shareholders may view the entry of a specialized biotechnology investment firm as a positive signal regarding the company's long-term value.
Next Steps
- The reporting persons are required to file amendments to this Schedule 13G if there are material changes in their percentage of ownership.
Key Dates
| Date | Description |
|---|---|
| 2026-02-20 | Date of shares outstanding count used for calculation. |
| 2026-02-26 | Date of issuer's 10-K filing. |
| 2026-05-01 | Date of event requiring the filing. |
| 2026-05-08 | Date of the Schedule 13G filing. |
Keywords
Viridian Therapeutics, Deep Track Capital, Schedule 13G, Biotechnology, Institutional Ownership, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.